Sirexatamab is a monoclonal antibody commercialized by Leap Therapeutics, with a leading Phase II program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 14 clinical trials, of which 6 were completed, 6 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Sirexatamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sirexatamab is expected to reach an annual total of $137 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Leap Therapeutics Overview
Leap Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. FL-301, a monoclonal antibody that targets Claudin18.2, is being tested in patients with gastric and pancreatic cancer. The company has an agreement with BeiGene Ltd for development rights and commercialization of DKN-01 in Australia, Asia (excluding Japan) and New Zealand. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$56.8 million in FY2022, compared to an operating loss of US$41.4 million in FY2021. The net loss of the company was US$54.6 million in FY2022, compared to a net loss of US$40.6 million in FY2021.
For a complete picture of Sirexatamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.